Many human cancers, including breast and pancreatic cancers, harbor aberrant Stat3 that functions as a master regulator of events that promote tumor formation and progression. Blocking aberrant Stat3 activity induces cancer cell growth inhibition and apoptosis, and tumor regression in mouse models. Given the number of human tumors with aberrant Stat3 activity, there is a high commercial potential for Stat3 inhibitors as novel anticancer drugs. Moreover, effective and selective Stat3 inhibitors will provide excellent molecular probes to interrogate Stat3 signaling to advance our understanding of the molecular mechanisms by which this protein mediates carcinogenesis, and provide new directions to thwart the functions of the aberrant protein. By computational modeling that exploited the key structural requirements for Stat3 activation, together with in silico screening of the NCI's Diversity and Plated sets chemical libraries, we identified agents, NSC 42067, NSC 59263 and NSC 74859, as binders of Stat3-SH2 domain and inhibitors of Stat3 DNA-binding activity (IC50 of 65-86

Public Health Relevance

Many human cancers harbor abnormal Stat3 activity that functions as a master regulator of events that promote tumor formation and progression. Blocking abnormal Stat3 activity induces cancer cell growth inhibition, apoptosis, and tumor regression in mouse models. Effective and selective Stat3 inhibitors are excellent research tools to interrogate Stat3 signaling to advance our understanding of the mechanisms leading to cancer, and represent potential new anticancer agents. Our proposal defines the molecular and biological properties of novel agents as Stat3-selective inhibitors that possess antitumor activity and that may be suitable for development into novel anticancer drugs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA128865-02
Application #
7685297
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Lees, Robert G
Project Start
2008-09-10
Project End
2012-07-31
Budget Start
2009-08-01
Budget End
2010-07-31
Support Year
2
Fiscal Year
2009
Total Cost
$182,007
Indirect Cost
Name
University of Central Florida
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
150805653
City
Orlando
State
FL
Country
United States
Zip Code
32826
Li, Chun-Shun; Yang, Bao-Jun; Turkson, James et al. (2017) Anti-proliferative ambuic acid derivatives from Hawaiian endophytic fungus Pestalotiopsis sp. FT172. Phytochemistry 140:77-82
Hilliard, Tyvette S; Miklossy, Gabriella; Chock, Christopher et al. (2017) 15?-methoxypuupehenol Induces Antitumor Effects In Vitro and In Vivo against Human Glioblastoma and Breast Cancer Models. Mol Cancer Ther 16:601-613
Li, Chunshun; Sarotti, Ariel M; Turkson, James et al. (2017) Verbenanone, an octahydro-5H-chromen-5-one from a Hawaiian-Plant Associated Fungus FT431. Tetrahedron Lett 58:2290-2293
Li, Chunshun; Sarotti, Ariel M; Yang, Baojun et al. (2017) A New N-methoxypyridone from the Co-Cultivation of Hawaiian Endophytic Fungi Camporesia sambuci FT1061 and Epicoccum sorghinum FT1062. Molecules 22:
Miklossy, Gabriella; Hilliard, Tyvette S; Turkson, James (2013) Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 12:611-29
Wason, Melissa S; Colon, Jimmie; Das, Soumen et al. (2013) Sensitization of pancreatic cancer cells to radiation by cerium oxide nanoparticle-induced ROS production. Nanomedicine 9:558-69
Zhang, Xiaolei; Yue, Peibin; Page, Brent D G et al. (2012) Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 109:9623-8
Mitra, Rajendra N; Doshi, Mona; Zhang, Xiaolei et al. (2012) An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery. Biomaterials 33:1500-8
Yue, P; Zhang, X; Paladino, D et al. (2012) Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells. Oncogene 31:2309-22
Page, Brent D G; Fletcher, Steven; Yue, Peibin et al. (2011) Identification of a non-phosphorylated, cell permeable, small molecule ligand for the Stat3 SH2 domain. Bioorg Med Chem Lett 21:5605-9

Showing the most recent 10 out of 28 publications